---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-009623"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:06:12.888963+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharma Q2 2023 net loss $28.4M; completes acquisition of two migraine products

## Summary
- Net loss $28.4M ($2.68/sh) vs $27.4M ($7.64/sh) in Q2 2022; R&D expense rose to $22.0M from $16.6M.
- Cash & equivalents $25.6M at June 30, down from $120.2M at Dec 31, 2022; raised $7.0M in Aug 2023 offering.
- Closed acquisition of Zembrace SymTouch and Tosymra from Upsher-Smith for $15M plus $10M inventory; trailing sales ~$30M.
- Enrolled four CNS trials: RESILIENT fibromyalgia (Q4 topline), PREVAIL Long COVID (Q3), PREVENTION chronic migraine (Q4), UPLIFT MDD (Q4).

## SEC filing metadata
- accession: 0001387131-23-009623
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/0001387131-23-009623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/tnxp_8k-081023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-009623
- JSON: https://secwatch.observer/filing/0001387131-23-009623.json
- Plain text: https://secwatch.observer/filing/0001387131-23-009623.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/0001387131-23-009623-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.